A Pre-Approval Information Exchange (PIE) Webinar, presented by Capricor Therapeutics.

Join this AMCP PIE webinar for an overview of deramiocel, an investigational therapy under FDA review for Duchenne muscular dystrophy (DMD). The session will review DMD disease burden, unmet needs in upper-limb and cardiac function, and available pre-approval clinical, safety, and administration information to support payer and formulary planning.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Sanofi.

This webinar will examine the long-term safety profile of efanesoctocog alfa in hemophilia A, drawing upon evidence from clinical studies and emerging real-world experience. Expert faculty will review key safety and efficacy outcomes with long-term treatment experience, and practical considerations relevant to patient management. The session will also explore how real-world utilization and outcomes complement clinical trial findings to provide a more comprehensive understanding of the therapy's performance in routine care. Attendees will gain insights into the evolving evidence base supporting treatment decisions for patients with hemophilia A.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Incyte.

This PIE webinar on tafasitamab-cxix + lenalidomide + R-CHOP in Frontline DLBCL will cover disease state and epidemiology, the current treatment landscape, and key clinical/safety data, followed by a brief Q&A

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Revolution Medicines.

Revolution Medicines will present results from the Phase 3 RASolute 302 study evaluating daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, in previously treated patients with metastatic pancreatic adenocarcinoma (PDAC). The PIE presentation will feature an overview of PDAC disease background, current second-line standard of care, and RASolute 302 study design elements and data.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP Member Webinar.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Vertex.

IgA nephropathy is a rare, progressive, B cell-driven kidney disease associated with clinical and economic burden. This webinar will review IgA nephropathy disease burden, unmet need, the recently updated 2025 KDIGO guidelines, and interim clinical outcomes from the Phase 1/2 and 3 trials of povetacicept, an investigational product from Vertex Pharmaceuticals that is being evaluated for the treatment of adults with IgA nephropathy. The safety and effectiveness have not been established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar you must be registered as a user of FormularyDecisions. 

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP AI LINK Group Webinar.

AI is everywhere—but separating buzz from practical value is the hard part. In this webinar, we’ll tackle common misconceptions, walk through real examples, and explore how organizations can use AI more effectively across workflows and decision-making. Attendees will leave with a sharper understanding of where AI can make an impact today—and what it takes to use it well.

An AMCP Member Webinar.

Population health and managed care pharmacy are often discussed as separate concepts, yet much of today’s pharmacy work sits squarely at their intersection. This webinar is designed to introduce the basics, creating a shared foundation of language and understanding for professionals working across health systems, payers, pharmaceutical organizations, and related settings. Participants will explore how population health, value-based care, and managed care pharmacy overlap in practice—even when professionals don’t identify their work as managed care. By clarifying terminology and roles, this session helps attendees better understand where they fit within the broader healthcare ecosystem and how their work aligns with AMCP’s mission.